# A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD

> **NCT05231785** · PHASE1 · RECRUITING · sponsor: **Alnylam Pharmaceuticals** · enrollment: 60 (estimated)

## Conditions studied

- Early-Onset Alzheimer Disease

## Interventions

- **DRUG:** ALN-APP
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05231785
- **Lead sponsor:** Alnylam Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-02-04
- **Primary completion:** 2029-04-20
- **Final completion:** 2029-04-20
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05231785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05231785, "A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD". Retrieved via AI Analytics 2026-08-22 from https://api.ai-analytics.org/clinical/NCT05231785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*